Biotech Values

[DewDiligence]

>> I would think if AGI-1067 is truly reducing plaque, a statistically significant decrease in cardiac events is a slam dunk. They only need a 20% reduction in events from ARISE to be successful. <<

I respectfully disagree about the slam dunk characterization. It is almost always a lot harder to show a tangible clinical benefit than to show merely an improvement in a biological marker.

If you are long AGIX, you have to be feeling pretty good about today’s price action. Could have been a lot worse.

I think the phase-2b study is too screwed up to be of much value as a second registration trial. If it were up to me, I would be talking to the FDA now about designing a new phase-2/3 pivotal (with an SPA of course) to complement the pivotal in progress. JMHO